Ident. | Authors (with country if any) | Title |
---|
000020 |
Santiago Perez-Lloret [France] ; María Ver Nica Rey [France] ; James Crispo [Canada] ; Daniel Krewski [Canada] ; Marise Lapeyre-Mestre [France] ; Jean-Louis Montastruc [France] ; Olivier Rascol [France] | Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients |
000083 |
Santiago Perez-Lloret [France, Argentine] ; Maria Veronica Rey [France] ; Pietro Lucca Ratti [France] ; Olivier Rascol [France] | Rotigotine transdermal patch for the treatment of Parkinson's Disease |
000086 |
Stéphane Thobois [France] ; Eugénie Lhommee [France] ; Hélène Klinger [France] ; Claire Ardouin [France] ; Emmanuelle Schmitt [France] ; Amélie Bichon [France] ; Andrea Kistner [France] ; Anna Castrioto [France] ; JING XIE [France] ; Valerie Fraix [France] ; Pierre Pelissier [France] ; Stephan Chabardes [France] ; Patrick Mertens [France] ; Jean-Louis Quesada [France] ; Jean-Luc Bosson [France] ; Pierre Pollak [France] ; Emmanuel Broussolle [France] ; Paul Krack [France] | Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil |
000224 |
Santiago Perez-Lloret [France] ; Maria Veronica Rey [France] ; Nelly Fabre [France] ; Fabienne Ory [France] ; Umberto Spampinato [France] ; Jean-Louis Montastruc [France] ; Olivier Rascol [France] | Do Parkinson's disease patients disclose their adverse events spontaneously? |
000299 |
Susan H. Fox [Canada] ; Regina Katzenschlager [Autriche] ; Shen-Yang Lim [Malaisie] ; Bernard Ravina [États-Unis] ; Klaus Seppi [Autriche] ; Miguel Coelho [Portugal] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz [États-Unis] ; Cristina Sampaio [Portugal] | The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Motor Symptoms of Parkinson's Disease |
000321 |
Cristina Sampaio [Portugal] ; Juliana Bronzova [Pays-Bas] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Serge V. Van De Witte [Pays-Bas] ; Ad Theeuwes [Pays-Bas] | Pardoprunox in Early Parkinson's Disease: Results from 2 Large, Randomized Double-Blind Trials |
000326 |
Olivier Rascol [France] ; Andres Lozano [Canada] ; Matthew Stern [États-Unis] ; Werner Poewe [Autriche] | Milestones in Parkinson's Disease Therapeutics |
000461 |
Robert A. Hauser [États-Unis] ; Anthony H. V. Schapira [Royaume-Uni] ; Olivier Rascol [France] ; Paolo Barone [Italie] ; Yoshikuni Mizuno [Japon] ; Laurence Salin [France] ; Monika Haaksma [Autriche] ; Nolwenn Juhel [France] ; Werner Poewe [Autriche] | Randomized, Double-Blind, Multicenter Evaluation of Pramipexole Extended Release Once Daily in Early Parkinson's Disease |
000472 |
Olivier Rascol [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] ; Anne-Marie Bonnet [France] ; Christine Brefel-Courbon [France] ; Pierre Cesaro [France] ; Philippe Damier [France] ; Bérengère Debilly [France] ; Frank Durif [France] ; Monique Galitzky [France] ; Jean-Marie Grouin [France] ; Sylvie Pennaforte [France] ; Gabriel Villafane [France] ; Sadek Yaici [France] ; Yves Agid [France] | Orodispersible Sublingual Piribedil to Abort OFF Episodes: A Single Dose Placebo-Controlled, Randomized, Double-Blind, Cross-Over Study |
000497 |
Olivier Rascol [France] ; Paolo Barone [Italie] ; Robert A. Hauser [États-Unis] ; Yoshikuni Mizuno [Japon] ; Werner Poewe [Autriche] ; Anthony H. V. Schapira [Royaume-Uni] ; Laurence Salin [France] ; Mandy Sohr [Allemagne] ; Catherine Debieuvre [France] | Efficacy, Safety, and Tolerability of Overnight Switching from Immediate- to Once Daily Extended-Release Pramipexole in Early Parkinson's Disease |
000500 |
Juliana Bronzova [Pays-Bas] ; Cristina Sampaio [Portugal] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Ad Theeuwes [Pays-Bas] ; Serge V. Van De Witte [Pays-Bas] ; Guus Van Scharrenburg [Pays-Bas] | Double-Blind Study of Pardoprunox, a New Partial Dopamine Agonist, in Early Parkinson's Disease |
000502 |
Santiago Perez-Lloret [France, Argentine] ; Olivier Rascol [France] | Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinson's Disease |
000548 |
Fabienne Ory-Magne [France] ; Christine Brefel-Courbon [France] ; Olivier Rascol [France] | Les agonistes dopaminergiques |
000644 |
Joëlle Micallef [France] ; Marc Rey [France] ; Alexandre Eusebio [France] ; Christine Audebert [France] ; Frank Rouby [France] ; Elisabeth Jouve [France] ; Sophie Tardieu [France] ; Oliver Blin [France] | Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects |
000856 |
Dieter Scheller [Allemagne] ; PIU CHAN [République populaire de Chine] ; QIN LI [Royaume-Uni] ; TAO WU [République populaire de Chine] ; RENLING ZHANG [République populaire de Chine] ; LE GUAN [République populaire de Chine] ; Paula Ravenscroft [Royaume-Uni] ; Celine Guigoni [France] ; Alan R. Crossman [Royaume-Uni] ; Michael Hill [Royaume-Uni] ; Erwan Bezard [France] | Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease |
000968 |
Alexandre Castro-Caldas [Portugal] ; Paul Delwaide [Belgique] ; Wolfgang Jost [Allemagne] ; Marcelo Merello [Argentine] ; Adrian Williams [Royaume-Uni] ; Paolo Lamberti [Italie] ; Miguel Aguilar [Espagne] ; Susanna Del Signore [France] ; Pierre Cesaro [France] | The parkinson-control study : A 1-year randomized, double- blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in parkinson's disease |
000978 |
Stéphane Thobois [France] | Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease : A review of the literature |
000A86 |
Stéphane Thobois [France] ; Florence Delamarre-Damier [France] ; Pascal Derkinderen [France] | Treatment of motor dysfunction in Parkinson's disease: an overview |
000B26 |
Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] | Evidence-based medical review update : Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004 |
000B60 |
Peter Jenner [Royaume-Uni] | A novel dopamine agonist for the transdermal treatment of Parkinson's disease |
000B98 |
Hélène Legros [France] ; Marie-George Dingeval [France] ; Francois Janin [France] ; Jean Costentin [France] ; Jean-Jacques Bonnet [France] | Toxicity of a treatment associating dopamine and disulfiram for catecholaminergic neuroblastoma SH-SY5Y cells: Relationships with 3,4-dihydroxyphenylacetaldehyde formation |
000C12 |
M. A. Silverdale [Royaume-Uni] ; S. L. Nicholson [Royaume-Uni] ; P. Ravenscroft [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; M. J. Millan [France] ; J. M. Brotchie [Canada] | Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate |
000C52 |
Makoto Naoi [Japon] ; Wakako Maruyama [Japon] ; Georgy M. Nagy [Hongrie] | Dopamine-derived salsolinol derivatives as endogenous monoamine oxidase inhibitors: Occurrence, metabolism and function in human brains |
000C60 |
N. Hamaue [Japon] ; M. Minami [Japon] ; M. Terado [Japon] ; M. Hirafuji [Japon] ; T. Endo [Japon] ; M. Machida [Japon] ; T. Hiroshige [Japon] ; A. Ogata [Japon] ; K. Tashiro [Japon] ; H. Saito [Japon] ; S. H. Parvez [France] | Comparative study of the effects of isatin, an endogenous MAO-inhibitor, and selegiline on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by the Japanese encephalitis virus |
000C85 |
F. Ghawche [France] ; F. Durif [France] | Traitement dopaminergique et syndromes parkinsoniens |
000D22 |
J.-L. Montastruc [France] ; L. Schmitt [France] ; H. Bagheri [France] | Comportement pathologique de jeu au cours d'une maladie de Parkinson traitée par lévodopa et bromocriptine |
000D70 |
Olivier Rascol [France] ; Pierre Payoux [France, Portugal] ; Fabienne Ory [France] ; Joaquim J. Ferreira [France] ; Christine Brefel-Courbon [France] ; Jean-Louis Montastruc [France] | Limitations of current Parkinson's disease therapy. Discussion |
000E28 |
A. Destee [France] ; R. Bordet [France] | Stimulation dopaminergique continue, stimulation dopaminergique pulsatile |
000E33 |
O. Rascol [France] ; J.-J. Ferreira [Portugal] ; P. Payoux [France] ; Ch. Brefel-Courbon [France] ; J.-L. Montastruc [France] | Prise en charge des dyskinésies par la lévodopa |
000E63 |
F. Durif [France] | Fluctuations motrices |
000E89 |
Estelle Rousselet [France] ; Jacques Callebert [France] ; Karine Parain [France] ; Chantal Joubert [France] ; Stéphane Hunot [France] ; Andreas Hartmann [France] ; Claude Jacque [France] ; Fernando Perez-Diaz [France] ; Charles Cohen-Salmon [France] ; Jean-Marie Launay [France] ; Etienne C. Hirsch [France] | Role of TNF-α receptors in mice intoxicated with the parkinsonian toxin MPTP |
000F30 |
H. E. Junginger [Pays-Bas] | Iontophoretic delivery of apomorphine: from in-vitro modelling to the Parkinson patient |
000F34 |
A. Angles [France] ; H. Bagheri [France] ; S. Saivin [France] ; J. L. Montastruc [France] | Interaction between lansoprazole and bromocriptine in a patient with Parkinson's disease |
000F44 |
Aïcha Douhou [France] ; Thomas Debeir [France] ; Mario Gustavo Murer [Argentine] ; Louis Do [France] ; Noëlle Dufour [France] ; Véronique Blanchard [France] ; Saliha Moussaoui [France] ; Georg Andrees Bohme [France] ; Yves Agid [France] ; Rita Raisman-Vozari [France] | Effect of chronic treatment with riluzole on the nigrostriatal dopaminergic system in weaver mutant mice |
000F63 |
C. Lebrun-Frenay [France] ; M. Borg [France] | Choosing the right dopamine agonist for patients with Parkinson's disease |
000F80 |
K. Ray Chaudhuri [Royaume-Uni] ; Suvankar Pal [Royaume-Uni] ; Christine Brefel-Courbon [France] | 'Sleep attacks' or 'Unintended sleep episodes' occur with dopamine agonists: Is this a class effect? |
001030 |
Jean-Louis Montastruc [France] ; Christine Brefel-Courbon [France] ; Jean-Michel Senard [France] ; Haleh Bagheri [France] ; Joaquim Ferreira [France] ; Olivier Rascol [France] ; Maryse Lapeyre-Mestre [France] | Sleep attacks and antiparkinsonian drugs : A pilot prospective pharmacoepidemiologic study |
001060 |
O. Rascol [France] ; J. G. Nutt [États-Unis] ; O. Blin [France] ; C. G. Goetz [États-Unis] ; J. M. Trugman [États-Unis] ; C. Soubrouillard [France] ; J. H. Carter [États-Unis] ; L. J. Currie [États-Unis] ; N. Fabre [France] ; C. Thalamas [France] ; W. J. Giardina [États-Unis] ; S. Wright [États-Unis] | Induction by Dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with parkinson Disease |
001079 |
Olivier Rascol [France] ; Joaquim J. Ferreira [Portugal] ; Claire Thalamas [France] ; Monique Galitsky [France] ; Jean-Louis Montastruc [France] | Dopamine agonists: Their role in the management of Parkinson's disease |
001085 |
Alberto Albanese [Italie] ; Ubaldo Bonuccelli [Italie] ; Christine Brefel [France] ; K. Ray Chaudhuri [Royaume-Uni] ; Carlo Colosimo [Italie] ; Tobias Eichhorn [Allemagne] ; Eldad Melamed [Israël] ; Pierre Pollak [France] ; Teus Van Laar [Pays-Bas] ; Mario Zappia [Italie] | Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease |
001172 |
L. A. Smith [Royaume-Uni] ; M. G. Jackson [Royaume-Uni] ; C. Bonhomme [France] ; C. Chezaubernard [France] ; K. B. Pearce [Royaume-Uni] ; P. Jenner [Royaume-Uni] | Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset |
001176 |
O. Rascol [France] | The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease |
001179 |
Saliha Moussaoui [France] ; Maria-Carmen Obinu [France] ; Nadine Daniel [France] ; Michel Reibaud [France] ; Véronique Blanchard [France] ; Assunta Imperato [France] | The antioxidant Ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease |
001181 |
J. J. Ferreira [France, Portugal] ; M. Galitzky [France] ; J. L. Montastruc [France] ; O. Rascol [France] | Sleep attacks and Parkinson's disease treatment |
001216 |
H. Allain [France] ; A. Destee [France] ; H. Petit [France] ; M. Patay [France] ; S. Schück [France] ; D. Bentue-Ferrer [France] ; P. Le Cavorzin [France] | Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease |
001242 |
D. C. Rogers [Royaume-Uni] ; B. Costall [Royaume-Uni] ; A. M. Domeney [France] ; P. A. Gerrard [Royaume-Uni] ; M. Greener [Royaume-Uni] ; M. E. Kelly [Royaume-Uni] ; J. J. Hagan [Royaume-Uni] ; A. J. Hunter [Royaume-Uni] | Anxiolytic profile of ropinirole in the rat, mouse and common marmoset |
001248 |
O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; A. D. Korczyn [Israël] ; P. P. De Deyn [Belgique] ; C. E. Clarke [Royaume-Uni] ; A. E. Lang [Canada] | A five-year study of the incidence of dyskinesia in patients with early parkinson's disease who were treated with ropinirole or levodopa |
001282 |
G. L. Defer [France] | Controverse sur le traitement initial de la maladie de parkinson : L-dopa ou agonistes dopaminergiques ? |
001283 |
O. Rascol [France] | Arguments en faveur du traitement précoce de la maladie de Parkinson par les agonistes dopaminergiques |
001329 |
C. Thalamas [France] ; A. Taylor [Royaume-Uni] ; C. Brefel-Courbon [France] ; S. Eagle [Royaume-Uni] ; K. Fitzpatrick [Royaume-Uni] ; O. Rascol [France] | Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease |
001342 |
| Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated Parkinsonian patients |
001355 |
S. Champagne [France] ; E. Coste [France] ; H. Peyriere [France] ; J. Nigond [France] ; E. Mania [France] ; M. Pons [France] ; D. Hillaire-Buys [France] ; P. Balmes [France] ; J.-P. Blayac [France] ; J.-M. Davy [France] | Chronic constrictive pericarditis induced by long-term bromocriptine therapy : Report of two cases |
001371 |
H. Bagheri [France] ; C. Damase-Michel [France] ; M. Lapeyre-Mestre [France] ; S. Cismondo [France] ; D. O'Connell [Irlande (pays)] ; J.-M. Senard [France] ; O. Rascol [France] ; J.-L. Montastruc [France] | A study of salivary secretion in Parkinson's disease |
001590 |
U. K. Rinne [Finlande] ; F. Bracco [Italie] ; C. Chouza [Uruguay] ; E. Dupont [Danemark] ; O. Gershanik [Argentine] ; J. F. Marti Masso [Espagne] ; J. L. Montastruc [France] ; C. D. Marsden [Royaume-Uni] ; A. Dubini [Italie] ; N. Orlando [Italie] ; R. Grimaldi [Italie] | Cabergoline in the treatment of early Parkinson's disease : Results of the first year of treatment in a double-blind comparison of cabergoline and levodopa |
001740 |
D. Muguet [France] ; E. Broussolle ; G. Chazot | Apomorphine in patients with Parkinson's disease : Parkinson's disease |
001814 |
F. Tison [France] ; N. Fouillet ; P. Henry | Apomorphine increases blood glucose concentrations in Parkinson's disease |
001827 |
E. Courty [France] ; F. Durif [France] ; P. Courty [France] ; A.-J. Coudert [France] | Sexe, délire et Parkinson: un effet inattendu de l'apomorphine? Réflexion à propos de quatre observations |
001831 |
G. Fenelon [France] | Maladie de Parkinson: traitements d'exception et perspectives |
001842 |
F. Goulley [France] ; Y. Wolmark [France] ; I. Bourdeix [France] ; P. D. Chaumet-Riffaud [France] | Introduction du Parlodel® en association précoce à la lévodopa dans le traitement de la maladie de Parkinson : comparaison de deux progressions posologiques |
001865 |
C. L. Gervason [France] ; P. R. Pollak ; P. Limousin ; J. E. Perret | Reproducibility of motor effects induced by successive subcutaneous apomorphine injections in Parkinson's disease |
001867 |
F. Durif [France] ; M. Paire [France] ; D. Deffond [France] ; A. Eschalier [France] ; G. Dordain [France] ; M. Tournilhac [France] ; J. Lavarenne [France] | Relation between clinical efficacy and pharmacokinetic parameters after sublingual apomorphine in Parkinson's disease |
001868 |
E. Nicolle [France] ; P. Pollak [France] ; F. Serre-Debeauvais [France] ; P. Richard [France] ; C. L. Gervason [France] ; E. Broussolle [France] ; M. Gavend [France] | Pharmacokinetics of apomorphine in parkinsonian patients |
001893 |
J. L. Montastruc [France] ; O. Rascol ; J. M. Senard | Current status of dopamine agonists in Parkinson's disease management |
001898 |
D. Deffond [France] ; F. Durif ; M. Tournilhac | Apomorphine in treatment of Parkinson's disease : comparison between subcutaneous and sublingual routes |
001902 |
| Système nerveux autonome et maladie de Parkinson. Influence des médicaments antiparkinsoniens |
001941 |
F. Durif [France] ; D. Deffond [France] ; A. Eschalier [France] ; M. Tournilhac [France] | Administration de l'apomorphine par voie subliguale dans le traitement des fluctuations motrices de la maladie de Parkinson |
001948 |
O. Rascol [France] ; U. Sabatini ; F. Chollet ; P. Celsis ; J.-L. Montastruc ; J.-P. Marc-Vergnes ; A. Rascol | Supplementary and primary sensory motor area activity in Parkinson's disease : regional cerebral blood flow changes during finger movements and effects of apomorphine |
001968 |
| |
001970 |
P. Vermersch [France] ; J. Fondarai [France] ; H. Petit | Étude randomisée sur une année de l'association précoce L-dopa/lisuride dans la maladie de Parkinson |
001973 |
B. Claudel ; M. C. Hardy-Bayle ; J. F. Allilaire | Un délire sous bromocriptine |
001979 |
S. Ammar [France] ; P. Martin | Modélisations des effets des agonistes dopaminergiques en psychopharmacologie : vers une homothétie clinique et expérimentale |
001996 |
P. Pollak [France] ; C. L. Gervason | Application de l'apomorphine au traitement de la maladie de Parkinson |
001998 |
J. L. Montrastuc [France] ; O. Rascol ; J. M. Senard ; V. Gualano ; H. Bagheri ; G. Houin ; A. Lees ; A. Rascol | Sublingual apomorphine in Parkinson's disease : a clinical and pharmacokinetic study |
001999 |
U. Sabatini [France] ; O. Rascol ; P. Celsis ; G. Houin ; A. Rascol ; J. P. Marc-Vergnes ; J. L. Montastruc | Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms |
001A03 |
F. Durif [France] ; E. Jeanneau [France] ; F. Serre-Debeauvais ; D. Deffond ; A. Eschalier [France] ; M. Tournilhac | Relation between plasma concentration and clinical efficacy after sublingual single dose apomorphine in Parkinson's disease |
001A04 |
J. L. Montastruc [France] | Recent advances in the clinical pharmacology of Parkinson's disease |
001A16 |
H. Allain ; F. Le Coz ; F. Goulley ; F. Brunet-Bourgin ; Y. Loria ; D. Bentue-Ferrer ; R. Decombe ; J.-M. Reymann ; P. Chaumet-Riffaud ; J.-M. Gandon | Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians : a randomized double-lind crossover study |
001A31 |
H. Allain ; D. Bentueê-Ferrer ; J. L. Merot ; R. Decombe | Pharmacologie des agonistes dopaminergiques |
001A43 |
J. L. Montastruc ; O. Rascol ; A. Rascol | Comparison de la bromocriptine et de la levodopa dans le traitement de première intention de la maladie de Parkinson : résultats à 3 ans d'une étude prospective randomisée |
001A47 |
P. Pollak ; A. S. Champay ; J. M. Gaio ; M. Hommel ; A. L. Benabid ; J. Perret | Administration sous-cutanée d'apomorphine des les fluctuations motrices de la maladie de Parkinson |
001A51 |
D. Milon [France] ; H. Allain ; J. M. Reymann ; G. Morel ; O. Sabouraud ; J. Van Den Driessche | Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatis hypotension in parkinsonians |
001A53 |
U. Sabatini ; O. Rascol ; A. Rascol ; J.-L. Montastruc | Migraine attacks induced by subcutaneous apomorphine in two migrainous parkinsonian patients |
001A62 |
O. Rascol ; N. Fabre ; H. Teraêvaêinen ; Werner Poewe [Autriche] ; C. Luêcking ; U. Rinne ; E. Dupont ; D. Hirt ; M. Hoyer ; X. Lataste | CQA 206-291 : a novel dopamine agonist in the treatment of Parkinson's disease |
001A71 |
J. M. Mayer | Traitement d'une maladie de Parkinson |
001B00 |
B. Pillon ; B. Dubois ; A.-M. Bonnet ; M. Esteguy ; J. Guimaraes ; J.-M. Vigouret ; F. Lhermitte ; Yves Agid [France] | Cognitive slowing in Parkinson's disease fails to respond to levodopa treatment: the 15-objects test |
001B01 |
O. Rascol ; M. Clanet ; J. L. Montastruc ; M. Simonetta ; M. J. Soulier-Esteve ; B. Doyon ; A. Rascol | Abnormal ocular movements in Parkinson's disease: evidence for involvement of dopaminergic systems |
001B15 |
M. Ziegler | L'évolution du parkinsonien traité |
001B17 |
J.-P. Marc-Vergnes ; P. Celsis ; J. L. Montastruc ; J. F. Demonet ; A. Agniel ; O. Rascol ; G. Viallard ; B. Doyon ; A. Rascol | Hémodynamique cérébrale et pharmacologie clinique dans la maladie de Parkinson |
001B20 |
J. L. Montastruc ; O. Rascol ; A. Rascol | Bromocriptine versus levodopa dans le traitement de première intention de la maladie de Parkinson. Premiers résultats à deux ans |
001B73 |
B. Dubois ; Yves Agid [France] | Les agonistes dopaminergiques dans la maladie de Parkinson |
001B78 |
A. Rascol ; J. L. Montastruc ; O. Rascol ; J. M. Senard | Mesulergine (CU 32-085) in the treatment of Parkinson's disease |